Tag: life sciences
-
New Funds Awarded for Rapid Infection Diagnostics
A developer of faster infection diagnostics is receiving another $8.2 million from an international group supporting solutions to antibiotic resistant microbes.
-
Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised
A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems.
-
“Dark Genome” Drug Discoverer Gains $37M in Early Funds
19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University of Oxford medical school. Nucleome Therapeutics is seeking new treatments for…
-
Trial Shows Wearable Device Can Reduce Migraine
Results from a clinical trial show an electronic device worn on the arm can reduce migraine occurrences in people with history of the condition.
-
Trial Begins Testing RNA Hepatitis-B Treatment
A clinical trial is underway testing the safety and chemical activity of a hepatitis-B therapy using engineered RNA to block production of a key protein linked to the disease.
-
Hydrogel Biomaterials Company Raises $3M in Early Funds
A developer of bioactive hydrogels as alternatives to animal models for drug discovery and clinical lab tests is raising $3 million in its first venture round.
-
Start-Up to Manufacture, Supply Practical Radiation Drugs
A new company formed by a technology venture investor and the Mayo Clinic aims to produce and supply more readily available radiation drug therapies.
-
Gene Therapy Stimulates Missing Enzymes in Rare Disease
Results from a clinical trial show an experimental gene therapy for Krabbe disease is safe and produces enzymes missing in children with the rare disease.
-
Drug Licensed for Precision Autism Spectrum Therapies
A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress.
-
RNA Cancer Immunotherapy Shown Feasible in Preclinical Test
Tests with lab animals show synthetic viral RNA particles, encased in natural oils, can safely invoke an immune response to attack solid tumors.